DK1355940T3 - Urotensin II-agonister og -antagonister - Google Patents

Urotensin II-agonister og -antagonister

Info

Publication number
DK1355940T3
DK1355940T3 DK01987763T DK01987763T DK1355940T3 DK 1355940 T3 DK1355940 T3 DK 1355940T3 DK 01987763 T DK01987763 T DK 01987763T DK 01987763 T DK01987763 T DK 01987763T DK 1355940 T3 DK1355940 T3 DK 1355940T3
Authority
DK
Denmark
Prior art keywords
urotensin
agonists
antagonists
features
antagonist
Prior art date
Application number
DK01987763T
Other languages
English (en)
Inventor
David H Coy
Wojciech J Rossowski
John E Taylor
Original Assignee
Univ Tulane
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane, Sod Conseils Rech Applic filed Critical Univ Tulane
Application granted granted Critical
Publication of DK1355940T3 publication Critical patent/DK1355940T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57509Corticotropin releasing factor [CRF] (Urotensin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK01987763T 2000-10-20 2001-10-19 Urotensin II-agonister og -antagonister DK1355940T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24189600P 2000-10-20 2000-10-20
PCT/US2001/050724 WO2002032932A2 (en) 2000-10-20 2001-10-19 Urotensin-ii agonists and antagonists

Publications (1)

Publication Number Publication Date
DK1355940T3 true DK1355940T3 (da) 2008-01-07

Family

ID=22912605

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01987763T DK1355940T3 (da) 2000-10-20 2001-10-19 Urotensin II-agonister og -antagonister

Country Status (21)

Country Link
US (2) US7241737B2 (da)
EP (1) EP1355940B1 (da)
JP (2) JP4081369B2 (da)
KR (3) KR100820896B1 (da)
AT (1) ATE374786T1 (da)
AU (2) AU3290302A (da)
BR (1) BR0114737A (da)
CA (1) CA2425804A1 (da)
CZ (1) CZ299402B6 (da)
DE (1) DE60130802T2 (da)
DK (1) DK1355940T3 (da)
ES (1) ES2291372T3 (da)
HU (1) HUP0301384A3 (da)
IL (2) IL155127A0 (da)
MX (1) MXPA03003297A (da)
NO (1) NO20031699L (da)
PL (1) PL366327A1 (da)
PT (1) PT1355940E (da)
RU (1) RU2263679C2 (da)
WO (1) WO2002032932A2 (da)
ZA (1) ZA200302505B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050014198A1 (en) * 2002-07-11 2005-01-20 Leong Ng Assays and kits for detecting and monitoring heart disease
US7939052B2 (en) * 2005-05-12 2011-05-10 Janssen Pharmaceutica Nv Method of measuring the biological activity of an urotensin II receptor
CA2666642C (en) 2006-10-16 2015-11-17 The Salk Institute For Biological Studies Receptor(sstr2)-selective somatostatin antagonists
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
AU2008360223B2 (en) * 2008-08-08 2014-06-19 Polyphor Ag Template-fixed peptidomimetics
RU2558921C1 (ru) * 2014-06-26 2015-08-10 Анатолий Петрович Бахтинов Способ прекращения течки у самок и остро проявляющейся охоты у самцов млекопитающих животных

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3881467T2 (de) * 1987-10-09 1993-10-21 Agency Ind Science Techn Vasokonstriktor-Peptid.
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US20020107187A1 (en) * 1996-05-22 2002-08-08 Kingston David J. Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
US6262229B1 (en) * 1996-12-04 2001-07-17 Biomeasure Incorporated Somatostatin antagonists
US6159700A (en) * 1997-01-27 2000-12-12 Smithkline Beecham Corporation Method of finding agonist and antagonist to human and rat GPR14
FR2786489B1 (fr) 1998-11-26 2002-12-27 Inst Nat Sante Rech Med Urotensines ii de mammiferes et leurs appications
EP1233774A4 (en) * 1999-11-29 2004-06-16 Smithkline Beecham Corp UROTENSIN II ANALOGS
CZ299362B6 (cs) * 2001-03-08 2008-07-02 The Administrators Of The Tulane Educational Fund Antagonisté somatostatinu
EP1397150A4 (en) * 2001-04-09 2005-01-26 Administrators Ofthe Tulane Ed Somatostatin agonists

Also Published As

Publication number Publication date
KR20030081316A (ko) 2003-10-17
JP2005500244A (ja) 2005-01-06
KR100820896B1 (ko) 2008-04-11
US20070287665A1 (en) 2007-12-13
DE60130802D1 (de) 2007-11-15
US7241737B2 (en) 2007-07-10
EP1355940B1 (en) 2007-10-03
NO20031699D0 (no) 2003-04-11
JP2006342170A (ja) 2006-12-21
HK1059938A1 (en) 2004-07-23
ZA200302505B (en) 2005-05-30
ES2291372T3 (es) 2008-03-01
JP4081369B2 (ja) 2008-04-23
KR20060090768A (ko) 2006-08-16
KR20060090843A (ko) 2006-08-16
US20050075480A1 (en) 2005-04-07
HUP0301384A3 (en) 2010-04-28
AU2002232903B2 (en) 2005-06-30
CZ299402B6 (cs) 2008-07-16
RU2263679C2 (ru) 2005-11-10
ATE374786T1 (de) 2007-10-15
BR0114737A (pt) 2005-06-07
WO2002032932A2 (en) 2002-04-25
MXPA03003297A (es) 2004-05-04
HUP0301384A2 (en) 2007-11-28
AU3290302A (en) 2002-04-29
EP1355940A2 (en) 2003-10-29
NO20031699L (no) 2003-06-18
PT1355940E (pt) 2007-11-08
CZ2003900A3 (cs) 2003-12-17
IL184121A0 (en) 2007-10-31
KR100795427B1 (ko) 2008-01-17
CA2425804A1 (en) 2002-04-25
WO2002032932A3 (en) 2003-09-04
KR100707408B1 (ko) 2007-04-13
PL366327A1 (en) 2005-01-24
DE60130802T2 (de) 2008-07-03
IL155127A0 (en) 2003-10-31

Similar Documents

Publication Publication Date Title
ATE293989T1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
ATE286897T1 (de) Morpholinderivate als antagonisten an orexinrezeptoren
DE60309481D1 (de) Cyclische n-aroylamine als orexinrezeptorantagonisten
EA200200208A1 (ru) Синергитическая композиция
EA200001176A1 (ru) Гетероциклические ингибиторы p38
DE69532162D1 (de) Cannabinoid-rezeptor-antagonisten
DE69728585D1 (de) Mittel gegen Juckreiz
ATE312811T1 (de) Benzamidinderivate als antagonisten von orexinrezeptoren
IL184121A0 (en) Urotensin-ii agonists polypeptide and its use for manufacture of medicaments
DE60226161D1 (de) 3-azabicyclo(3.1.0)hexan derivative als antagonisten der opioid rezeptoren
ATE406159T1 (de) Behandlung von hyperlipidämie
ATE284398T1 (de) N-imidazolyl-alkyl substituierte cyklische amine als histamin-h3 agonisten oder antagonisten
ATE366572T1 (de) 5-ht 1b/1d rezeptor agonisten zur behandlung von kopfschmerz der aus der verabreichung von endothelin rezeptor antagonisten resultiert
DE60015187D1 (de) Urotensin-ii rezeptorantagonisten
EA200401137A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
TR200002072T2 (tr) Spiropiperidin türevleri
EP1878743A3 (en) Urotensin-II agonists and antagonists
SE0001373D0 (sv) NPY Y1 receptor agonists and antagonists
IS8388A (is) Blandan af serótónín endurupptökuhindra og histamín 3 viðtaka mótlyfi, öflugum verka eða hlutaverka
DK1420789T3 (da) Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling
EA200400116A1 (ru) Сочетание действующих веществ для фармакологического лечения никотиновой зависимости
ITFI20030238A1 (it) Peptidi ciclici antagonisti dell'urotensina-ii
EP1463817A4 (en) HISTAMINE RECEPTOR H3 POLYNUCLEOTIDES
ATE320005T1 (de) Testverfahren für agonisten oder antagonisten der bindung von dynorphin a an den mas-rezeptor
MX2007013207A (es) Agente para la profilaxis y tratamiento de la pancreatitis.